S. Savage

593 total citations
8 papers, 493 citations indexed

About

S. Savage is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, S. Savage has authored 8 papers receiving a total of 493 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S. Savage's work include HER2/EGFR in Cancer Research (6 papers), Angiogenesis and VEGF in Cancer (4 papers) and Colorectal Cancer Treatments and Studies (2 papers). S. Savage is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Angiogenesis and VEGF in Cancer (4 papers) and Colorectal Cancer Treatments and Studies (2 papers). S. Savage collaborates with scholars based in United States and Netherlands. S. Savage's co-authors include Herbert I. Hurwitz, Afshin Dowlati, A. Benjamin Suttle, Lini Pandite, Jeffrey P. Hodge, Elmar M. Merkle, D. Gibson, Shermini Saini, Peter Ho and David Collins and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Molecular Cancer Therapeutics.

In The Last Decade

S. Savage

8 papers receiving 478 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Savage United States	7	297	261	258	112	51	8	493
James A. Onori United States	4	236 0.8×	224 0.9×	254 1.0×	123 1.1×	46 0.9×	5	500
Teresa M. Hopper United States	4	231 0.8×	204 0.8×	243 0.9×	101 0.9×	46 0.9×	6	486
D. Gibson United States	7	234 0.8×	250 1.0×	207 0.8×	76 0.7×	50 1.0×	10	454
Amogh Boloor United States	5	219 0.7×	194 0.7×	247 1.0×	89 0.8×	46 0.9×	5	500
A. Van Oosterom Belgium	11	209 0.7×	268 1.0×	228 0.9×	124 1.1×	34 0.7×	28	572
Sasja F. Mulder Netherlands	12	340 1.1×	253 1.0×	265 1.0×	130 1.2×	34 0.7×	38	669
Maja J. De Jonge Netherlands	16	298 1.0×	449 1.7×	471 1.8×	114 1.0×	91 1.8×	43	849
S. Bartholomeus Belgium	9	190 0.6×	380 1.5×	295 1.1×	229 2.0×	82 1.6×	17	670
L. Wood United States	12	333 1.1×	185 0.7×	254 1.0×	126 1.1×	34 0.7×	23	481
Markus Faghih Germany	2	257 0.9×	285 1.1×	357 1.4×	152 1.4×	118 2.3×	3	705

Countries citing papers authored by S. Savage

Since Specialization

Citations

This map shows the geographic impact of S. Savage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Savage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Savage more than expected).

Fields of papers citing papers by S. Savage

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Savage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Savage. The network helps show where S. Savage may publish in the future.

Co-authorship network of co-authors of S. Savage

This figure shows the co-authorship network connecting the top 25 collaborators of S. Savage. A scholar is included among the top collaborators of S. Savage based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Savage. S. Savage is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Jonge, Maja J.A. de, Paul Hamberg, Jaap Verweij, et al.. (2012). Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Investigational New Drugs. 31(3). 751–759. 29 indexed citations

2.

Hurwitz, Herbert I., Afshin Dowlati, Shermini Saini, et al.. (2009). Phase I Trial of Pazopanib in Patients with Advanced Cancer. Clinical Cancer Research. 15(12). 4220–4227. 333 indexed citations

3.

Chiorean, Elena G., Christopher Sweeney, S. Savage, et al.. (2007). Phase I dose-escalation study of the anti-VEGFR-2 recombinant human IgG1 MAb IMC-1121B administered every other week (q2w) or every 3 weeks (q3w) in patients (pts) with advanced cancers. Molecular Cancer Therapeutics. 6. 12 indexed citations

4.

Nixon, Andrew B., Jason D. Allen, Elizabeth A. Miller, et al.. (2007). Clinical evaluation of nitric oxide responses to anti-VEGF therapy with bevacizumab. Journal of Clinical Oncology. 25(18_suppl). 14039–14039. 3 indexed citations

5.

Savage, S., Jaap Verweij, F. Eskens, et al.. (2006). A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently. Journal of Clinical Oncology. 24(18_suppl). 3088–3088. 21 indexed citations

6.

Hurwitz, Herbert I., Afshin Dowlati, S. Savage, et al.. (2005). Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. Journal of Clinical Oncology. 23(16_suppl). 3012–3012. 64 indexed citations

7.

Suttle, A. Benjamin, et al.. (2004). Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3054–3054. 20 indexed citations

8.

Suttle, A. Benjamin, et al.. (2004). Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3054–3054. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact